Small-Molecule Targeting of BET Proteins in Cancer

Advances in Cancer Research

Volumn 131, Issue , 2016, Pages 21-58

  French, C A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BET inhibitor; BRD2; BRD3; BRD4; BRD4 NUT; BRDT; Bromodomain; Cancer; Chromatin; Epigenetic; NUT midline carcinoma

Indexed keywords

BRD2 PROTEIN; BRD3 PROTEIN; BRD4 PROTEIN; BRDT PROTEIN; BROMODOMAIN AND EXTRATERMINAL PROTEIN; BROMODOMAIN INHIBITOR; E1A ASSOCIATED P300 PROTEIN; NUT PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRD1 PROTEIN, HUMAN; BRD2 PROTEIN, HUMAN; BRD3 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; MOLECULAR LIBRARY; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG TOLERABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; THERAPEUTIC USE;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RNA-BINDING PROTEINS; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

EID: 84973541949     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2016.04.001     Document Type: Chapter

References (133)

1. Adam, R.C., Yang, H., Rockowitz, S., Larsen, S.B., Nikolova, M., Oristian, D.S. et al., Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature 521 (2015), 366–370.
2. Alekseyenko, A.A., Walsh, E.M., Wang, X., Grayson, A.R., Hsi, P.T., Kharchenko, P.V. et al., The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes & Development 29 (2015), 1507–1523.
3. Anand, P., Brown, J.D., Lin, C.Y., Qi, J., Zhang, R., Artero, P.C. et al., BET bromodomains mediate transcriptional pause release in heart failure. Cell 154 (2013), 569–582.
4. Aronow, B.J., Ebert, C.A., Valerius, M.T., Potter, S.S., Wiginton, D.A., Witte, D.P. et al., Dissecting a locus control region: Facilitation of enhancer function by extended enhancer-flanking sequences. Molecular Cell. Biology 15 (1995), 1123–1135.
5. Asangani, I.A., Dommeti, V.L., Wang, X., Malik, R., Cieslik, M., Yang, R. et al., Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510 (2014), 278–282.
6. Bahr, B. L., Maughan, K. S., Soh, K. K., Bearss, J. J., Kim, W., Peterson, P., et al. (2015 Apr 18–22). Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia. In Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA. Philadelphia (PA): AACR Cancer Research. 75 (15 Suppl.), 2015, Abstract number 2698.
7. Bandukwala, H.S., Gagnon, J., Togher, S., Greenbaum, J.A., Lamperti, E.D., Parr, N.J. et al., Selective inhibition of CD4 + T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 14532–14537.
8. Bauer, D., Mitchell, C., Strait, K., Lathan, C., Stelow, E., Lueer, S. et al., Clinicopathologic features and long-term outcomes of nut midline carcinoma. Clinical Cancer Research 18 (2012), 5773–5779.
9. Beesley, A.H., Stirnweiss, A., Ferrari, E., Endersby, R., Howlett, M., Failes, T.W. et al., Comparative drug screening in NUT midline carcinoma. British Journal of Cancer 110 (2014), 1189–1198.
10. Belkina, A.C., Denis, G.V., BET domain co-regulators in obesity, inflammation and cancer. Nature Reviews Cancer 12 (2012), 465–477.
11. Belkina, A.C., Nikolajczyk, B.S., Denis, G.V., BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. The Journal of Immunology 190 (2013), 3670–3678.
12. Bisgrove, D.A., Mahmoudi, T., Henklein, P., Verdin, E., Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proceedings of the National Academy of Sciences of the United States of America 104 (2007), 13690–13695.
13. Borbely, G., Haldosen, L.A., Dahlman-Wright, K., Zhao, C., Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget 6 (2015), 33623–33635.
14. Caterina, J.J., Ciavatta, D.J., Donze, D., Behringer, R.R., Townes, T.M., Multiple elements in human beta-globin locus control region 5' HS 2 are involved in enhancer activity and position-independent, transgene expression. Nucleic Acids Research 22 (1994), 1006–1011.
15. Chaidos, A., Caputo, V., Karadimitris, A., Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: Emerging preclinical and clinical evidence. Therapeutic Advances in Hematology 6 (2015), 128–141.
16. Chapuy, B., McKeown, M.R., Lin, C.Y., Monti, S., Roemer, M.G., Qi, J. et al., Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24 (2013), 777–790.
17. Chase, A., Cross, N.C., Aberrations of EZH2 in cancer. Clinical Cancer Research 17 (2011), 2613–2618.
18. Chau, N.G., Mitchell, C.M., Aserlind, A., Grunfeld, N., Kaplan, L., Bauer, D.E. et al., Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN). Journal of Clinical Oncology, 32, 2014 2014 ASCO Annual Meeting Abstracts.
19. Ciabrelli, F., Cavalli, G., Chromatin-driven behavior of topologically associating domains. Journal of Molecular Biology 427 (2015), 608–625.
20. Crawford, N.P., Alsarraj, J., Lukes, L., Walker, R.C., Officewala, J.S., Yang, H.H. et al., Bromodomain 4 activation predicts breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America 105 (2008), 6380–6385.
21. Crowley, T.E., Kaine, E.M., Yoshida, M., Nandi, A., Wolgemuth, D.J., Reproductive cycle regulation of nuclear import, euchromatic localization, and association with components of Pol II mediator of a mammalian double-bromodomain protein. Molecular Endocrinology 16 (2002), 1727–1737.
22. Dash, A., Gilliland, D.G., Molecular genetics of acute myeloid leukaemia. Best Practice & Research Clinical Haematology 14 (2001), 49–64.
23. Davis, B.N., Karabakhtsian, R.G., Pettigrew, A.L., Arnold, S.M., French, C.A., Brill, Y.M., Nuclear protein in testis midline carcinomas: A lethal and underrecognized entity. Archives of Pathology & Laboratory Medicine 135 (2011), 1494–1498.
24. Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I. et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 (2011), 529–533.
25. Deb, G., Thakur, V.S., Gupta, S., Multifaceted role of EZH2 in breast and prostate tumorigenesis: Epigenetics and beyond. Epigenetics 8 (2013), 464–476.
26. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M. et al., BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146 (2011), 904–917.
27. Denis, G.V., Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discovery Medicine 10 (2010), 489–499.
28. Denis, G.V., Green, M.R., A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. Genes & Development 10 (1996), 261–271.
29. Denis, G.V., McComb, M.E., Faller, D.V., Sinha, A., Romesser, P.B., Costello, C.E., Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. Journal of Proteome Research 5 (2006), 502–511.
30. Denis, G.V., Vaziri, C., Guo, N., Faller, D.V., RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth & Differentiation 11 (2000), 417–424.
31. Devaiah, B.N., Lewis, B.A., Cherman, N., Hewitt, M.C., Albrecht, B.K., Robey, P.G. et al., BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 6927–6932.
32. Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., Ozato, K., The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proceedings of the National Academy of Sciences of the United States of America 100 (2003), 8758–8763.
33. Dey, A., Ellenberg, J., Farina, A., Coleman, A.E., Maruyama, T., Sciortino, S. et al., A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Molecular Cell. Biology 20 (2000), 6537–6549.
34. Dey, A., Nishiyama, A., Karpova, T., McNally, J., Ozato, K., Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Molecular Biology of the Cell 20 (2009), 4899–4909.
35. Dhalluin, C., Carlson, J.E., Zeng, L., He, C., Aggarwal, A.K., Zhou, M.M., Structure and ligand of a histone acetyltransferase bromodomain. Nature 399 (1999), 491–496.
36. Digan, M.E., Haynes, S.R., Mozer, B.A., Dawid, I.B., Forquignon, F., Gans, M., Genetic and molecular analysis of fs(1)h, a maternal effect homeotic gene in Drosophila. Developmental Biology 114 (1986), 161–169.
37. Emadali, A., Rousseaux, S., Bruder-Costa, J., Rome, C., Duley, S., Hamaidia, S. et al., Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Molecular Medicine 5 (2013), 1180–1195.
38. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O. et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
39. Evans, A.G., French, C.A., Cameron, M.J., Fletcher, C.D., Jackman, D.M., Lathan, C.S. et al., Pathologic characteristics of nut midline carcinoma arising in the mediastinum. The American Journal of Surgical Pathology 36 (2012), 1222–1227.
40. Filippakopoulos, P., Knapp, S., The bromodomain interaction module. FEBS Letters 586 (2012), 2692–2704.
41. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.P., Barsyte-Lovejoy, D. et al., Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149 (2012), 214–231.
42. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O. et al., Selective inhibition of BET bromodomains. Nature 468 (2010), 1067–1073.
43. Fischer, E.S., Bohm, K., Lydeard, J.R., Yang, H., Stadler, M.B., Cavadini, S. et al., Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512 (2014), 49–53.
44. Fiskus, W., Sharma, S., Qi, J., Shah, B., Devaraj, S.G., Leveque, C. et al., BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular Cancer Therapeutics 13 (2014), 2315–2327.
45. Fiskus, W., Sharma, S., Qi, J., Valenta, J.A., Schaub, L.J., Shah, B. et al., Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular Cancer Therapeutics 13 (2014), 1142–1154.
46. Floyd, S.R., Pacold, M.E., Huang, Q., Clarke, S.M., Lam, F.C., Cannell, I.G. et al., The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 498 (2013), 246–250.
47. Fong, C.Y., Gilan, O., Lam, E.Y., Rubin, A.F., Ftouni, S., Tyler, D. et al., BET inhibitor resistance emerges from leukaemia stem cells. Nature 525 (2015), 538–542.
48. French, C.A., Demystified molecular pathology of NUT midline carcinomas. Journal of Clinical Pathology 63 (2010), 492–496.
49. French, C.A., Pathogenesis of NUT midline carcinoma. Annual Review of Pathology 7 (2012), 247–265.
50. French, C., NUT midline carcinoma. Nature Reviews Cancer 14 (2014), 149–150.
51. French, C.A., den Bakker, M.A., NUT carcinoma. 2015, International Agency for Research on Cancer (IARC), Lyon, France.
52. French, C.A., Kutok, J.L., Faquin, W.C., Toretsky, J.A., Antonescu, C.R., Griffin, C.A. et al., Midline carcinoma of children and young adults with NUT rearrangement. Journal of Clinical Oncology 22 (2004), 4135–4139.
53. French, C.A., Miyoshi, I., Aster, J.C., Kubonishi, I., Kroll, T.G., Dal Cin, P. et al., BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). The American Journal of Pathology 159 (2001), 1987–1992.
54. French, C.A., Miyoshi, I., Kubonishi, I., Grier, H.E., Perez-Atayde, A.R., Fletcher, J.A., BRD4-NUT fusion oncogene: A novel mechanism in aggressive carcinoma. Cancer Research 63 (2003), 304–307.
55. French, C.A., Rahman, S., Walsh, E.M., Kuhnle, S., Grayson, A.R., Lemieux, M.E. et al., NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism. Cancer Discovery 4 (2014), 928–941.
56. French, C.A., Ramirez, C.L., Kolmakova, J., Hickman, T.T., Cameron, M.J., Thyne, M.E. et al., BRD-NUT oncoproteins: A family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27 (2008), 2237–2242.
57. Gamsjaeger, R., Webb, S.R., Lamonica, J.M., Billin, A., Blobel, G.A., Mackay, J.P., Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Molecular Cell. Biology 31 (2011), 2632–2640.
58. Garcia, P.L., Miller, A.L., Kreitzburg, K.M., Council, L.N., Gamblin, T.L., Christein, J.D. et al., The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene 35 (2015), 833–845.
59. Grayson, A.R., Walsh, E.M., Cameron, M.J., Godec, J., Ashworth, T., Ambrose, J.M. et al., MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 33 (2014), 1736–1742.
60. Greenwald, R.J., Tumang, J.R., Sinha, A., Currier, N., Cardiff, R.D., Rothstein, T.L. et al., E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 103 (2004), 1475–1484.
61. Gyuris, A., Donovan, D.J., Seymour, K.A., Lovasco, L.A., Smilowitz, N.R., Halperin, A.L. et al., The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochimica et Biophysica Acta 1789 (2009), 413–421.
62. Haack, H., Johnson, L.A., Fry, C.J., Crosby, K., Polakiewicz, R.D., Stelow, E.B. et al., Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. The American Journal of Surgical Pathology 33 (2009), 984–991.
63. Hargreaves, D.C., Horng, T., Medzhitov, R., Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138 (2009), 129–145.
64. Haruki, N., Kawaguchi, K.S., Eichenberger, S., Massion, P.P., Gonzalez, A., Gazdar, A.F. et al., Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. Journal of Medical Genetics 42 (2005), 558–564.
65. Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J.S., Gunatilake, D., Madore, J. et al., Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget 6 (2015), 21507–21521.
66. Henssen, A., Thor, T., Odersky, A., Heukamp, L., El-Hindy, N., Beckers, A. et al., BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4 (2013), 2080–2095.
67. Herait, P. E., Berthon, C., Thieblemont, C., et al. (2014 Apr 5–9). Abstract CT231: BETbromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: Interim results of an ongoing phase I trial in hematologic malignancies. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA. Philadelphia (PA): AACR Cancer Research. 74 (19 Suppl.), 2014, Abstract number CT231.
68. Herranz, D., Ambesi-Impiombato, A., Palomero, T., Schnell, S.A., Belver, L., Wendorff, A.A. et al., A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine 20 (2014), 1130–1137.
69. Houzelstein, D., Bullock, S.L., Lynch, D.E., Grigorieva, E.F., Wilson, V.A., Beddington, R.S., Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Molecular Cell. Biology 22 (2002), 3794–3802.
70. Jang, M.K., Mochizuki, K., Zhou, M., Jeong, H.S., Brady, J.N., Ozato, K., The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Molecular Cell 19 (2005), 523–534.
71. Jiang, Y.W., Veschambre, P., Erdjument-Bromage, H., Tempst, P., Conaway, J.W., Conaway, R.C. et al., Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 8538–8543.
72. Kanno, T., Kanno, Y., Siegel, R.M., Jang, M.K., Lenardo, M.J., Ozato, K., Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Molecular Cell 13 (2004), 33–43.
73. Kees, U.R., Mulcahy, M.T., Willoughby, M.L., Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). The American Journal of Pediatric Hematology/Oncology 13 (1991), 459–464.
74. Kubonishi, I., Takehara, N., Iwata, J., Sonobe, H., Ohtsuki, Y., Abe, T. et al., Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Research 51 (1991), 3327–3328.
75. Kuroda, S., Suzuki, S., Kurita, A., Muraki, M., Aoshima, Y., Tanioka, F. et al., Cytological features of a variant NUT midline carcinoma of the lung harboring the NSD3-NUT fusion gene: A case report and literature review. Case Reports in Pathology, 2015, 2015 572951.
76. Kwak, H., Lis, J.T., Control of transcriptional elongation. Annual Review of Genetics 47 (2013), 483–508.
77. Lamonica, J.M., Deng, W., Kadauke, S., Campbell, A.E., Gamsjaeger, R., Wang, H. et al., Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. Proceedings of the National Academy of Sciences of the United States of America 108 (2011), E159–E168.
78. Lee, A.C., Kwong, Y.I., Fu, K.H., Chan, G.C., Ma, L., Lau, Y.L., Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome. Cancer 72 (1993), 2273–2276.
79. LeRoy, G., Rickards, B., Flint, S.J., The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Molecular Cell 30 (2008), 51–60.
80. Li, Z., Guo, J., Wu, Y., Zhou, Q., The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Research 41 (2013), 277–287.
81. Li, G.Q., Guo, W.Z., Zhang, Y., Seng, J.J., Zhang, H.P., Ma, X.X. et al., Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget 7 (2015), 2462–2474.
82. Lockwood, W.W., Zejnullahu, K., Bradner, J.E., Varmus, H., Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 19408–19413.
83. Loven, J., Hoke, H.A., Lin, C.Y., Lau, A., Orlando, D.A., Vakoc, C.R. et al., Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153 (2013), 320–334.
84. Lu, G., Middleton, R.E., Sun, H., Naniong, M., Ott, C.J., Mitsiades, C.S. et al., The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343 (2014), 305–309.
85. Lupianez, D.G., Kraft, K., Heinrich, V., Krawitz, P., Brancati, F., Klopocki, E. et al., Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell 161 (2015), 1012–1025.
86. Maher, O.M., Christensen, A.M., Yedururi, S., Bell, D., Tarek, N., Histone deacetylase inhibitor for NUT midline carcinoma. Pediatric Blood & Cancer 62 (2015), 715–717.
87. Mazur, P.K., Herner, A., Mello, S.S., Wirth, M., Hausmann, S., Sanchez-Rivera, F.J. et al., Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine 21 (2015), 1163–1171.
88. McCleland, M.L., Mesh, K., Lorenzana, E., Chopra, V.S., Segal, E., Watanabe, C. et al., CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. The Journal of Clinical Investigation 126 (2016), 639–652.
89. Mele, D.A., Salmeron, A., Ghosh, S., Huang, H.R., Bryant, B.M., Lora, J.M., BET bromodomain inhibition suppresses TH17-mediated pathology. The Journal of Experimental Medicine 210 (2013), 2181–2190.
90. Mertens, F., Wiebe, T., Adlercreutz, C., Mandahl, N., French, C.A., Successful treatment of a child with t(15;19)-positive tumor. Pediatric Blood & Cancer 49 (2007), 1015–1017.
91. Mertz, J.A., Conery, A.R., Bryant, B.M., Sandy, P., Balasubramanian, S., Mele, D.A. et al., Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America 108 (2011), 16669–16674.
92. Muntean, A.G., Hess, J.L., The pathogenesis of mixed-lineage leukemia. Annual Review of Pathology 7 (2012), 283–301.
93. Nagoshi, H., Taki, T., Hanamura, I., Nitta, M., Otsuki, T., Nishida, K. et al., Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Research 72 (2012), 4954–4962.
94. Nakamura, Y., Umehara, T., Nakano, K., Jang, M.K., Shirouzu, M., Morita, S. et al., Crystal structure of the human BRD2 bromodomain: Insights into dimerization and recognition of acetylated histone H4. The Journal of Biological Chemistry 282 (2007), 4193–4201.
95. Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W. et al., Suppression of inflammation by a synthetic histone mimic. Nature 468 (2010), 1119–1123.
96. Pivot-Pajot, C., Caron, C., Govin, J., Vion, A., Rousseaux, S., Khochbin, S., Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Molecular Cell. Biology 23 (2003), 5354–5365.
97. Prinjha, R.K., Witherington, J., Lee, K., Place your BETs: The therapeutic potential of bromodomains. Trends in Pharmacological Sciences 33 (2012), 146–153.
98. Puissant, A., Frumm, S.M., Alexe, G., Bassil, C.F., Qi, J., Chanthery, Y.H. et al., Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discovery 3 (2013), 308–323.
99. Qiu, H., Jackson, A.L., Kilgore, J.E., Zhong, Y., Chan, L.L., Gehrig, P.A. et al., JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. Oncotarget 6 (2015), 6915–6930.
100. Rahman, S., Sowa, M.E., Ottinger, M., Smith, J.A., Shi, Y., Harper, J.W. et al., The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Molecular Cell. Biology 31 (2011), 2641–2652.
101. Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.S., Muhar, M. et al., Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525 (2015), 543–547.
102. Reynoird, N., Schwartz, B.E., Delvecchio, M., Sadoul, K., Meyers, D., Mukherjee, C. et al., Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. The EMBO Journal 29 (2010), 2943–2952.
103. Roe, J.S., Mercan, F., Rivera, K., Pappin, D.J., Vakoc, C.R., BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Molecular Cell 58 (2015), 1028–1039.
104. Schroder, S., Cho, S., Zeng, L., Zhang, Q., Kaehlcke, K., Mak, L. et al., Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. The Journal of Biological Chemistry 287 (2012), 1090–1099.
105. Schwartz, B.E., Hofer, M.D., Lemieux, M.E., Bauer, D.E., Cameron, M.J., West, N.H. et al., Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Research 71 (2011), 2686–2696.
106. Sengupta, S., Biarnes, M.C., Clarke, R., Jordan, V.C., Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. Breast Cancer Research and Treatment 150 (2015), 265–278.
107. Shahbazi, J., Liu, P.Y., Atmadibrata, B., Bradner, J.E., Marshall, G.M., Lock, R.B. et al., The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2016 Epub ahead of print.
108. Shang, E., Wang, X., Wen, D., Greenberg, D.A., Wolgemuth, D.J., Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Developmental Dynamics 238 (2009), 908–917.
109. Shehata, B., Steelman, C.K., Abramowsky, C.R., Olson, T., French, C., Saxe, D. et al., NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a two-year-old with a pancreatic/hepatic primary. Pediatric and Developmental Pathology 13 (2010), 481–485.
110. Shen, C., Ipsaro, J.J., Shi, J., Milazzo, J.P., Wang, E., Roe, J.S. et al., NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Molecular Cell 60 (2015), 847–859.
111. Shi, J., Vakoc, C.R., The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Molecular Cell 54 (2014), 728–736.
112. Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J.H. et al., Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clinical Cancer Research 19 (2013), 6183–6192.
113. Shu, S., Lin, C.Y., He, H.H., Witwicki, R.M., Tabassum, D.P., Roberts, J.M. et al., Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529 (2016), 413–417.
114. Stathis, A., Quesnel, B., Amorim, S., Thieblemont, .C., Zucca, E., Raffoux, E. et al., 5 LBA: Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. 26th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics, Vol. 50, 2014, 18–21.
115. Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.P., de La Motte Rouge, T. et al., Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discovery 6 (2016), 492–500 Epub ahead of print.
116. Stelow, E.B., Bellizzi, A.M., Taneja, K., Mills, S.E., Legallo, R.D., Kutok, J.L. et al., NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. The American Journal of Surgical Pathology 32 (2008), 828–834.
117. Stirnweiss, A., McCarthy, K., Oommen, J., Crook, M.L., Hardy, K., Kees, U.R. et al., A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma. Oncogenesis, 4, 2015, e174.
118. Stratikopoulos, E.E., Dendy, M., Szabolcs, M., Khaykin, A.J., Lefebvre, C., Zhou, M.M. et al., Kinase and BET inhibitors together clamp inhibition of pi3k signaling and overcome resistance to therapy. Cancer Cell 27 (2015), 837–851.
119. Stuhlmiller, T.J., Miller, S.M., Zawistowski, J.S., Nakamura, K., Beltran, A.S., Duncan, J.S. et al., Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Reports 11 (2015), 390–404.
120. Suzuki, S., Kurabe, N., Ohnishi, I., Yasuda, K., Aoshima, Y., Naito, M. et al., NSD3-NUT-expressing midline carcinoma of the lung: First characterization of primary cancer tissue. Pathology Research and Practice 211 (2014), 404–408.
121. Tanaka, M., Kato, K., Gomi, K., Yoshida, M., Niwa, T., Aida, N. et al., NUT midline carcinoma: Report of 2 cases suggestive of pulmonary origin. The American Journal of Surgical Pathology 36 (2012), 381–388.
122. Thompson-Wicking, K., Francis, R.W., Stirnweiss, A., Ferrari, E., Welch, M.D., Baker, E. et al., Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Oncogene 32 (2013), 4664–4674.
123. Toretsky, J.A., Jenson, J., Sun, C.C., Eskenazi, A.E., Campbell, A., Hunger, S.P. et al., Translocation (11;15;19): A highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. American Journal of Clinical Oncology 26 (2003), 300–306.
124. Tseng, Y.Y., Moriarity, B.S., Gong, W., Akiyama, R., Tiwari, A., Kawakami, H. et al., PVT1 dependence in cancer with MYC copy-number increase. Nature 512 (2014), 82–86.
125. Wang, F., Liu, H., Blanton, W.P., Belkina, A., Lebrasseur, N.K., Denis, G.V., Brd2 disruption in mice causes severe obesity without Type 2 diabetes. The Biochemical Journal 425 (2010), 71–83.
126. Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., Dhe-Paganon, S. et al., DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348 (2015), 1376–1381.
127. Wu, S.Y., Lee, A.Y., Lai, H.T., Zhang, H., Chiang, C.M., Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Molecular Cell 49 (2013), 843–857.
128. Xiang, J.F., Yin, Q.F., Chen, T., Zhang, Y., Zhang, X.O., Wu, Z. et al., Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Research 24 (2014), 513–531.
129. Yan, J., Diaz, J., Jiao, J., Wang, R., You, J., Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. The Journal of Biological Chemistry 286 (2011), 27663–27675.
130. Yang, Z., Yik, J.H., Chen, R., He, N., Jang, M.K., Ozato, K. et al., Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Molecular Cell 19 (2005), 535–545.
131. Zhang, W., Prakash, C., Sum, C., Gong, Y., Li, Y., Kwok, J.J. et al., Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4 + T cells. The Journal of Biological Chemistry 287 (2012), 43137–43155.
132. Zhu, J., Gaiha, G.D., John, S.P., Pertel, T., Chin, C.R., Gao, G. et al., Reactivation of latent HIV-1 by inhibition of BRD4. Cell Reports 2 (2012), 807–816.
133. Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A. et al., RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478 (2011), 524–528.